FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003150160> ?p ?o ?g. }

• W2003150160 endingPage "225" @default.
• W2003150160 startingPage "205" @default.
• W2003150160 abstract "Objectives: To assess 1) the effectiveness of male-predominant plasma transfusion strategy for preventing transfusion-related acute lung injury and related mortality; and 2) whether this effect varies across different patient subgroups. Design: Systematic Review and meta-analysis: Data were identified by querying MEDLINE and EMBASE (including proceedings of major conferences on blood transfusions), searching the Internet for hemovigilance reports, reviewing reference lists of eligible articles and contacting experts in the field. Eligible were all studies reporting transfusion-related acute lung injury incidence, all-cause mortality (primary outcomes), hospital length of stay, time to extubation, PaO2/FIO2-ratio or blood pressure changes (secondary outcomes) in recipients of plasma transfusions containing relatively more plasma from individuals at low risk of carrying leukocyte-antibodies (“male plasma”) than those receiving comparator plasma (“control plasma”). No limits were placed on study design, population or language. The only exclusion criteria were non-human subjects and lack of control group. Prespecified study quality indicators (including risk of bias assessment) and potential effect modifiers were tested using Cochran’s Q Test. Final analyses using random-effects models and I2 to assess heterogeneity were performed in the subset of studies judged to provide the best evidence and separately for significantly different subgroups using STATA 12.1 (StataCorp, College Station, TX). Setting: As per primary studies. Patients/Subjects: As per primary studies. Interventions: As per primary studies (generally: exposure to plasma containing relatively more male plasma than comparator plasma). Measurements and Main Results: From a total of 850 retrieved records, we identified 45 eligible studies. For transfusion-related acute lung injury incidence, final analysis was restricted to 13 cohort studies and one randomized controlled trial in which transfusion-related acute lung injury cases only involved plasma transfusions. Risk of transfusion-related acute lung injury and mortality in plasma recipients exposed to men when compared with control plasma were 0.27 (95% CI, 0.20–0.38; p < 0.001; I2 = 0%; n = 14; 286 events) and 0.89 (95% CI, 0.80–1.00; p = 0.04; I2 = 79%; n = 7; 5, 710 events), respectively. No other significant interactions were found. Secondary outcomes showed similar results but were less reported and the studies were more heterogeneous. Sensitivity analyses did not alter the results. There was no evidence of publication bias. Discussion: More than 800 million people in 17 countries are subject to male-predominant plasma transfusion policy and at least three more countries are planning or considering adoption of this strategy. On the basis of most observational data, judged to be of high quality, male-predominant plasma transfusion strategy reduces plasma-related transfusion-related acute lung injury incidence and possibly mortality. There was no evidence that the effect differs across patient subgroups, but power to detect such differences was low." @default.
• W2003150160 created "2016-06-24" @default.
• W2003150160 creator A5030553725 @default.
• W2003150160 creator A5032271832 @default.
• W2003150160 creator A5049053259 @default.
• W2003150160 creator A5054802858 @default.
• W2003150160 creator A5058549485 @default.
• W2003150160 creator A5072473046 @default.
• W2003150160 creator A5073834351 @default.
• W2003150160 creator A5079384485 @default.
• W2003150160 date "2015-01-01" @default.
• W2003150160 modified "2023-10-18" @default.
• W2003150160 title "Male-Predominant Plasma Transfusion Strategy for Preventing Transfusion-Related Acute Lung Injury" @default.
• W2003150160 cites W1495699649 @default.
• W2003150160 cites W1525854652 @default.
• W2003150160 cites W1546323384 @default.
• W2003150160 cites W1574760601 @default.
• W2003150160 cites W1605699249 @default.
• W2003150160 cites W1964095702 @default.
• W2003150160 cites W1964906546 @default.
• W2003150160 cites W1969460539 @default.
• W2003150160 cites W2004668542 @default.
• W2003150160 cites W2006057795 @default.
• W2003150160 cites W2015958583 @default.
• W2003150160 cites W2030322918 @default.
• W2003150160 cites W2034338541 @default.
• W2003150160 cites W2047454746 @default.
• W2003150160 cites W2051370790 @default.
• W2003150160 cites W2054375284 @default.
• W2003150160 cites W2063274101 @default.
• W2003150160 cites W2069146584 @default.
• W2003150160 cites W2069247057 @default.
• W2003150160 cites W2071688599 @default.
• W2003150160 cites W2076267546 @default.
• W2003150160 cites W2080903978 @default.
• W2003150160 cites W2090308649 @default.
• W2003150160 cites W2100198018 @default.
• W2003150160 cites W2101502513 @default.
• W2003150160 cites W2107328434 @default.
• W2003150160 cites W2113610709 @default.
• W2003150160 cites W2116398207 @default.
• W2003150160 cites W2120200067 @default.
• W2003150160 cites W2121530386 @default.
• W2003150160 cites W2125435699 @default.
• W2003150160 cites W2125660301 @default.
• W2003150160 cites W2129329533 @default.
• W2003150160 cites W2140878169 @default.
• W2003150160 cites W2143491379 @default.
• W2003150160 cites W2156003673 @default.
• W2003150160 cites W2156098321 @default.
• W2003150160 cites W2157475765 @default.
• W2003150160 cites W2157823046 @default.
• W2003150160 cites W2161328469 @default.
• W2003150160 cites W2161805977 @default.
• W2003150160 cites W2335121146 @default.
• W2003150160 cites W2991792334 @default.
• W2003150160 cites W4214757007 @default.
• W2003150160 doi "https://doi.org/10.1097/ccm.0000000000000675" @default.
• W2003150160 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25514705" @default.
• W2003150160 hasPublicationYear "2015" @default.
• W2003150160 type Work @default.
• W2003150160 sameAs 2003150160 @default.
• W2003150160 citedByCount "37" @default.
• W2003150160 countsByYear W20031501602014 @default.
• W2003150160 countsByYear W20031501602015 @default.
• W2003150160 countsByYear W20031501602016 @default.
• W2003150160 countsByYear W20031501602017 @default.
• W2003150160 countsByYear W20031501602018 @default.
• W2003150160 countsByYear W20031501602019 @default.
• W2003150160 countsByYear W20031501602020 @default.
• W2003150160 countsByYear W20031501602021 @default.
• W2003150160 countsByYear W20031501602022 @default.
• W2003150160 crossrefType "journal-article" @default.
• W2003150160 hasAuthorship W2003150160A5030553725 @default.
• W2003150160 hasAuthorship W2003150160A5032271832 @default.
• W2003150160 hasAuthorship W2003150160A5049053259 @default.
• W2003150160 hasAuthorship W2003150160A5054802858 @default.
• W2003150160 hasAuthorship W2003150160A5058549485 @default.
• W2003150160 hasAuthorship W2003150160A5072473046 @default.
• W2003150160 hasAuthorship W2003150160A5073834351 @default.
• W2003150160 hasAuthorship W2003150160A5079384485 @default.
• W2003150160 hasConcept C120665830 @default.
• W2003150160 hasConcept C121332964 @default.
• W2003150160 hasConcept C126322002 @default.
• W2003150160 hasConcept C177713679 @default.
• W2003150160 hasConcept C194828623 @default.
• W2003150160 hasConcept C2776468924 @default.
• W2003150160 hasConcept C2777259802 @default.
• W2003150160 hasConcept C2777714996 @default.
• W2003150160 hasConcept C2780014101 @default.
• W2003150160 hasConcept C2908647359 @default.
• W2003150160 hasConcept C44249647 @default.
• W2003150160 hasConcept C61511704 @default.
• W2003150160 hasConcept C71924100 @default.
• W2003150160 hasConcept C82789193 @default.
• W2003150160 hasConcept C99454951 @default.
• W2003150160 hasConceptScore W2003150160C120665830 @default.
• W2003150160 hasConceptScore W2003150160C121332964 @default.

• next